El 76 %
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El 76 %
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
El 76 %
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El 76 %
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Pacific Biosciences of California Inc
Cerrado
SectorSanidad
1.06 -3.64
Resumen
Variación precio
24h
Mínimo
1.04
Máximo
1.1
Ingresos | 63M 2.4M |
|---|---|
Ventas | -2.1M 37M |
BPA | -0.15 |
Margen de beneficios | 6.045 |
Empleados | 575 |
EBITDA | -420M -403M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +104.55% upside |
Próximas Ganancias | 6 ago 2025 |
|---|
Capitalización Mercado | -9M 330M |
|---|---|
Apertura anterior | 4.7 |
Cierre anterior | 1.06 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
173 / 382 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Bullish Evidence
Pacific Biosciences of California Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Pacific Biosciences of California Inc previsión
Precio Objetivo
By TipRanks
104.55% repunte
Estimación a 12 Meses
Media 2.25 USD 104.55%
Máximo 3 USD
Mínimo 1.5 USD
De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pacific Biosciences of California Inc Dist en los últimos 3 meses.
Sentimiento
By Acuity
173 / 382 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Pacific Biosciences of California Inc
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
